|View printer-friendly version|
|BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn® in Progressive Multiple Sclerosis|
"This important step toward the development of NurOwn® in progressive MS confirms our commitment to bring to the market innovative cellular therapies for neurodegenerative disease,” said
“We plan to quickly initiate the Phase 2 clinical study of NurOwn® in progressive MS to address the significant unmet need for MS patients,” said
MS affects approximately 1 million individuals in the U.S. and 2.3 million individuals worldwide. Approximately half of affected individuals will eventually develop progressive disease, which may lead to increasing levels of motor, visual, and cognitive functional impairment and disability.
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause